Cell Therapeutics, Inc. (NASDAQ: CTIC) is focused on leading the biopharmaceutical industry with their diversified portfolio of proprietary oncology drugs. They manage each and every aspect of the manufacturing process, but outsource their clinical and commercial active pharmaceutical ingredient (API) and finished product (FP) production activities to superior contract manufacturing organizations, both in the US and in Europe. For further information, visit the Company’s web site at www.ctiseattle.com.
- 17 years ago
QualityStocks
Cell Therapeutics, Inc. (NASDAQ: CTIC)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…